Startup Showcase: Rejuvenate Biomed: What do you think?

Rejuvenate Biomed are ready to take their first Longevity therapy into clinical trials: Invest, buy, or both?

It’s time to have your say on Rejuvenate Biomed.

We like Longevity therapies derived from existing ‘off-patent’ drugs and this is what Rejuvenate Biomed are doing; they’re de-risked, unencumbered by licensing complexities and have great results from their research … but that’s just our opinion – you’re the ones with the investment and buying potential: What do you think?

  • Watch the video pitch and investor questions;
  • Check-out the slide deck;
  • Take the 30 secs survey and see what others think!

The video pitch and investor questions:

The slide deck:

Rejuvenate Biomed Pitch Deck Longevity.Technology

First Longevity

The 30-second survey (with live results):

Would you like to know more?

We’re happy to pass along your comments and questions to the Rejuvenate Biomed team: you can email us via this link. Thanks.


Thanks for engaging – we have regular Startup Showcases coming-up: stay tuned!

First Longevity
Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Neurotech2020 – a clear head for neurotech, research and investment

Tomorrow's dreams today ... well, next week – it's Neurotech2020. Neurotech2020 – the digital congress for neurotechnology innovation and growth – is coming to (your...

Biotech Elevian announces $15m equity financing

The anti-aging company looks to the clinic with Prime Movers Lab leading the round. Massachusets-based Elevian announced this week that it had closed $15 million equity...

eGenesis advances xenotransplantation research

Reducing waiting lists and treating diabetes – eGenesis progresses xeno without the paradox. Recently we covered eGenesis' progress in its xenotransplantation research, as it attempts...

Review: WHOOP fitness tracker

We trialled this beautifully-understated fitness/sleep tracking device to see if it would make us whoop with joy or holler for something else.   GO LONG    GO...